Genmab Lands Experienced Partner AbbVie In Broad Bispecific Antibody Collaboration

 
• By Jessica Merrill

AbbVie will pay $750m up front plus up to $3.15bn in milestone fees to jointly develop and commercialize three bispecific antibody candidates for cancer and an earlier drug discovery collaboration.

Genmab Office Copenhagen - close up
Genmab hopes to grow into a commercial company • Source: Genmab

More from Deals

More from Business